Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction

Trial Profile

A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selatogrel (Primary)
  • Indications Myocardial infarction
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Idorsia Pharmaceuticals
  • Most Recent Events

    • 03 Sep 2019 Results published in the Idorsia Pharmaceuticals Media Release.
    • 03 Sep 2019 According to an Idorsia Pharmaceuticals Media release, the positive results from this study were presented at the European Society of Cardiology 2019 Congress(ESC 2019).
    • 18 Dec 2018 According to an Idorsia media release, the compny will present data from this study at upcoming scientific congress and published in scientific literature.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top